Title : Selexipag: First Global Approval.

Pub. Date : 2016 Mar

PMID : 26846322






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Selexipag (Uptravi( )) is a highly selective, long-acting, nonprostanoid, prostacyclin receptor agonist that is being developed by Actelion Pharmaceuticals Ltd and Nippon Shinyaku. selexipag prostaglandin I2 receptor Homo sapiens